A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes

References

• Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):1–11. doi:10.1038/s41598-020-71908-9
   PubMed Web of Science ®Google Scholar
• Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–281. doi:10.1016/j.diabres.2018.02.023
   PubMed Web of Science ®Google Scholar
• Jan Mohamed HJB, Yap RWK, Loy SL, Norris SA, Biesma R, Aagaard-Hansen J. Prevalence and determinants of overweight, obesity, and type 2 diabetes mellitus in adults in Malaysia. Asia Pac J Public Health. 2015;27(2):123–135. doi:10.1177/1010539514562447
   PubMed Web of Science ®Google Scholar
• Menke A, Rust KF, Fradkin J, Cheng YJ, Cowie CC. Associations between trends in race/ethnicity, aging, and body mass index with diabetes prevalence in the United States: a series of cross-sectional studies. Ann Intern Med. 2014;161(5):328–335. doi:10.7326/M14-0286
   PubMed Web of Science ®Google Scholar
• Murea M, Ma L, Freedman BI. Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications. Rev Diabet Stud. 2012;9(1):6. doi:10.1900/RDS.2012.9.6
   PubMedGoogle Scholar
• Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576(7785):51–60. doi:10.1038/s41586-019-1797-8
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Groop L, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers. 2015;1(1):1–22. doi:10.1038/nrdp.2015.19
   Web of Science ®Google Scholar
• Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:1–19. doi:10.7573/dic.212283
   Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853. doi:10.1016/S0140-6736(98)07019-6
   PubMed Web of Science ®Google Scholar
• Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med. 2013;369(14):1336–1343. doi:10.1056/NEJMra1109345
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251. doi:10.1111/dom.12932
   PubMed Web of Science ®Google Scholar
• Stoffel M, Espinosa R III, Michelle MLB, Bell GI. Human glucagon-like peptide-1 receptor gene: localization to chromosome band 6p21 by fluorescence in situ hybridization and linkage of a highly polymorphic simple tandem repeat DNA polymorphism to other markers on chromosome 6. Diabetes. 1993;42(8):1215–1218. doi:10.2337/diab.42.8.1215
   PubMed Web of Science ®Google Scholar
• Widmann C, Dolci W, Thorens B. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J. 1995;310(1):203–214. doi:10.1042/bj3100203
   PubMedGoogle Scholar
• Dillon JS, Tanizawa Y, Wheeler MB, et al. Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology. 1993;133(4):1907–1910. doi:10.1210/en.133.4.1907
   PubMed Web of Science ®Google Scholar
• Thorens B. Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci. 1992;89(18):8641–8645. doi:10.1073/pnas.89.18.8641
   PubMed Web of Science ®Google Scholar
• Tanizawa Y, Riggs AC, Elbein SC, Whelan A, Donis-Keller H, Permutt MA. Human glucagon-like peptide-1 receptor gene in NIDDM: identification and use of simple sequence repeat polymorphisms in genetic analysis. Diabetes. 1994;43(6):752–757. doi:10.2337/diab.43.6.752
   PubMed Web of Science ®Google Scholar
• Tokuyama Y, Matsui K, Egashira T, Nozaki O, Ishizuka T, Kanatsuka A. Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabetes Res Clin Pract. 2004;66(1):63–69. doi:10.1016/j.diabres.2004.02.004
   PubMed Web of Science ®Google Scholar
• Yagi T, Nishi S, Hinata SI, Murakami M, Yoshimi T. A population association study of four candidate genes (Hexokinase II, Glucagon‐like Peptide‐1 receptor, fatty acid binding Protein‐2, and Apolipoprotein c‐II) with type 2 diabetes and impaired glucose tolerance in Japanese Subjects. Diabetic Med. 1996;13(10):902–907. doi:10.1002/(SICI)1096-9136(199610)13:10<902::AID-DIA242>3.0.CO;2-O
   PubMed Web of Science ®Google Scholar
• Zhang Y, Cook JTE, Hattersley AT, et al. Non-linkage of the glucagon-like peptide 1 receptor gene with maturity onset diabetes of the young. Diabetologia. 1994;37(7):721–724. doi:10.1007/BF00417698
   PubMed Web of Science ®Google Scholar
• Montrose-Rafizadeh C, Wang Y, Janczewski AM, Henderson TE, Egan JM. Overexpression of glucagon-like peptide-1 receptor in an insulin-secreting cell line enhances glucose responsiveness. Mol Cell Endocrinol. 1997;130(1–2):109–117. doi:10.1016/S0303-7207(97)00079-8
   PubMed Web of Science ®Google Scholar
• Cooper DM. Regulation and organization of adenylyl cyclases and cAMP. Biochem J. 2003;375(3):517–529. doi:10.1042/bj20031061
   PubMedGoogle Scholar
• Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? Eur J Endocrinol. 2008;158(6):773. doi:10.1530/EJE-07-0804
   PubMed Web of Science ®Google Scholar
• Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535–539. doi:10.2337/diab.43.4.535
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157. doi:10.1053/j.gastro.2007.03.054
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153–165. doi:10.1016/j.cmet.2006.01.004
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234. doi:10.1056/NEJM199807233390404
   PubMed Web of Science ®Google Scholar
• Killilea T. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care. 2002;8(16 Suppl):S441–9. PMID: 12408407.
   PubMed Web of Science ®Google Scholar
• Gribble FM, Williams L, Simpson AK, Reimann F. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52(5):1147–1154. doi:10.2337/diabetes.52.5.1147
   PubMed Web of Science ®Google Scholar
• Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005;11(1):90–94. doi:10.1038/nm1168
   PubMed Web of Science ®Google Scholar
• Hansen L, Lampert S, Mineo H, Holst JJ. Neural regulation of glucagon-like peptide-1 secretion in pigs. Am J Physiol Endocrinol Metab. 2004;287(5):E939–E947. doi:10.1152/ajpendo.00197.2004
   PubMed Web of Science ®Google Scholar
• Freeman DO, S J. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76:S13. doi:10.3949/ccjm.76.s5.03
   PubMedGoogle Scholar
• Zhou J, Livak MF, Bernier M, et al. Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab. 2007;293(2):E538–E547. doi:10.1152/ajpendo.00070.2007
   PubMed Web of Science ®Google Scholar
• Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–7380. doi:10.1021/acs.jmedchem.5b00726
   PubMed Web of Science ®Google Scholar
• de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. Int J Clin Pharm. 2016;38(1):144–151. doi:10.1007/s11096-015-0219-8
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–2257. doi:10.1056/NEJMoa1509225
   PubMed Web of Science ®Google Scholar
• Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–1239. doi:10.1056/NEJMoa1612917
   PubMed Web of Science ®Google Scholar
• Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–1529. doi:10.1016/S0140-6736(18)32261-X
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. doi:10.1056/NEJMoa2108269
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3
   PubMed Web of Science ®Google Scholar
• Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409. doi:10.1016/S0140-6736(17)30069-7
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity. 2020;28(3):529–536. doi:10.1002/oby.22726
   PubMed Web of Science ®Google Scholar
• Ahmann A, Chow F, Vivian F, et al. Semaglutide provides superior glycemic control across SUSTAIN 1–5 clinical trials. Int J Nutrol. 2018;11(S 01):Trab722. doi:10.1055/s-0038-1675019
   Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6(4):275–286. doi:10.1016/S2213-8587(18)30024-X
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Meester ID, Durinx C, Bal G, et al. Natural substrates of dipeptidyl peptidase IV. Cellular Peptidases Immune Funct Dis. 2002;2:67–87. doi:10.1007/0-306-46826-3_7
   Google Scholar
• De Meester I, Lambeir AM, Proost P, Scharpé S. Dipeptidyl peptidase IV substrates. Adv Exp Med Biol. 2002;524:3–18.
   Web of Science ®Google Scholar
• Ahrén BO, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab. 2004;89(5):2078–2084. doi:10.1210/jc.2003-031907
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double‐blind, placebo‐controlled studies with single oral doses. Clin Pharmacol Ther. 2005;78(6):675–688. doi:10.1016/j.clpt.2005.09.002
   PubMed Web of Science ®Google Scholar
• Nauck MA, El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia. 2005;48(4):608–611. doi:10.1007/s00125-005-1704-8
   PubMed Web of Science ®Google Scholar
• Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003;46(13):2774–2789. doi:10.1021/jm030091l
   PubMed Web of Science ®Google Scholar
• Aroda VR, Rosenstock J, Terauchi Y, et al. Effect and safety of oral semaglutide monotherapy in type 2 diabetes—PIONEER 1 trial. Diabetes. 2018;67(Supplement_1). doi:10.2337/db18-2-LB
   Google Scholar
• Rosenstock J, Allison D, Birkenfeld AL, Blicher TM, Deenadayalan S, Jacobsen JB; PIONEER 3 Investigators. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480. doi:10.1001/jama.2019.2942
   PubMed Web of Science ®Google Scholar
• Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39–50. doi:10.1016/S0140-6736(19)31271-1
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515–527. doi:10.1016/S2213-8587(19)30192-5
   PubMed Web of Science ®Google Scholar
• Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. doi:10.1056/NEJMoa1901118
   PubMed Web of Science ®Google Scholar
• Buse JB, Bode BW, Mertens A, et al. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial. BMJ Open Diabetes Res Care. 2020;8(2):e001649. doi:10.1136/bmjdrc-2020-001649
   PubMed Web of Science ®Google Scholar
• Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial. Diabetes Care. 2019;42(12):2262–2271. doi:10.2337/dc19-0898
   PubMed Web of Science ®Google Scholar
• Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, Phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377–391. doi:10.1016/S2213-8587(20)30075-9
   PubMed Web of Science ®Google Scholar
• Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392–406. doi:10.1016/S2213-8587(20)30074-7
   PubMed Web of Science ®Google Scholar
• Wang L, Xin Q, Wang Y, et al. Efficacy and safety of liraglutide in type 2 diabetes mellitus patients complicated with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2021;171:105765. doi:10.1016/j.phrs.2021.105765
   PubMed Web of Science ®Google Scholar
• Azoulay L, Filion KB, Platt RW, et al. Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med. 2016;176(10):1464–1473. doi:10.1001/jamainternmed.2016.1522
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement_1):S90–S102. doi:10.2337/dc19-S009
   PubMedGoogle Scholar
• Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021;23(9):2177–2182. doi:10.1111/dom.14453
   PubMed Web of Science ®Google Scholar
• Zhong P, Zeng H, Huang M, He G, Chen Z. Efficacy and safety of subcutaneous and oral semaglutide administration in patients with type 2 diabetes: a meta-analysis. Front Pharmacol. 2021;2459. doi:10.3389/fphar.2021.695182
   Web of Science ®Google Scholar